Pay in 4 interest-free payments of $6.82 Learn more
Ships within 48 hours · Estimated delivery Oct 19 - Oct 24
Source: Jastreboff et al., NEJM 2023 TRIUMPH-4 Phase 3 (68 weeks, 445 participants) Phase 2 Type 2 Diabetes Trial (36 weeks, 281 participants) In the type 2 diabetes population, weight loss was lower than in the obesity trial which is consistent with the pattern seen across all GLP-1 drugs
However, at the 24-week mark, the magnitude of weight loss efficacy does not appear to be negatively affected by the lower baseline, including for Semaglutide and Tirzepatide
Pregnancy, Contraception and Breastfeeding Guidance GLP-1 medicines are not recommended during pregnancy or while trying to conceive due to insufficient safety evidence
Better glycemic control is still the goal in diabetes to prevent microvascular disease
Learn more about our unique, expert-led weight loss app today
US$ 28.12
US$ 22.10
US$ 19.98
US$ 23.08
US$ 23.19
US$ 23.67
US$ 25.15
US$ 20.82
